Related Research Articles
Elias Zerhouni is an Algerian-born American scientist, radiologist and biomedical engineer.
Claude H. Nash was CEO of Bloodstone Ventures plc. from 2007 to 2010. From 2004 to 2006 he was vice president, research and development at the University of Maryland Biotechnology Institute. He previously cofounded, and was CEO and chairman of, ViroPharma Incorporated, a pharmaceutical company. Before founding ViroPharma, Nash was vice president of infectious disease and cancer research at the Schering-Plough Research Institute.
Guy Salvesen is a South African-born biochemist, best known for his work in the field of apoptosis. His research focuses on proteases and their inhibitors in humans, with particular emphasis on the caspases of the apoptotic cell death pathway.
Anirvan Ghosh is an American neuroscientist and Biotech executive.
Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focusing on basic and translational research, with major research programs in cancer, neurodegeneration, diabetes, infectious, inflammatory, and childhood diseases. The institute also specializes in stem cell research and drug discovery technologies.
CHI-California Healthcare Institute is a private, non-profit public policy research and advocacy organization, representing more than 250 universities, academic research centers, biotechnology, and medical device companies. Founded in 1993, and based in La Jolla, California, CHI has offices in Washington, D.C., and Sacramento, California. CHI publishes an annual California Biomedical Industry report, providing data on the scope and scale of academic and commercial life sciences research and development within the state. In 2008, the industry employed more than 270,000 Californians and produced revenues in excess of $75 billion.
Sir Menelaos (Mene) Nicolas Pangalos is a British neuroscientist of Greek descent.
Aviv Regev is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. She is a core member at the Broad Institute of MIT and Harvard and professor at the Department of Biology of the Massachusetts Institute of Technology. Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project, together with Sarah Teichmann.
The Research & Development Council of New Jersey is a nonprofit organization which advocates for progress in various research and development sectors in the state of New Jersey. Its membership includes representatives from academia, industry, and government. Members of the council are offered services such as policy analysis and recent news in the fields of science research. The Research & Development Council of New Jersey was the principal fundraiser for the construction of the Liberty Science Center, and it also funds a dozen scholarships for New Jersey students yearly. The organization was established in 1962 and is based in Newark.
Richard H. Scheller is the former Chief Science Officer and Head of Therapeutics at 23andMe and the former Executive Vice President of Research and Early Development at Genentech. He was a professor at Stanford University from 1982 to 2001 before joining Genentech. He has been awarded the Alan T. Waterman Award in 1989, the W. Alden Spencer Award in 1993 and the NAS Award in Molecular Biology in 1997, won the 2010 Kavli Prize in Neuroscience with Thomas C. Südhof and James E. Rothman, and won the 2013 Albert Lasker Award for Basic Medical Research with Thomas Südhof. He was also given the Life Sciences Distinguished Alumni Award from University of Wisconsin–Madison. He is a Fellow of the American Academy of Arts and Sciences and a Member of the National Academy of Sciences.
John C. Lechleiter is an American businessman and chemist. He served as the President, Chief Executive Officer and Chairman of the Board of Directors of Eli Lilly and Company from April 2008 to December 2016. John Lechleiter's successor is David Ricks who assumed the role of president and CEO in January 2017. He is the eldest of nine children of Jeanne and John H. Lechleiter.
Roger M. Perlmutter is the former executive vice president of Merck & Co. and former president of Merck Research Laboratories. He is currently a non-executive director of Merck Research Laboratories.
Hal V. Barron is an American clinician-scientist and drug developer who served as president of research and development at GlaxoSmithKline from March 2018 until 2022, when he resigned in order to join the cellular reprogramming venture Altos Labs in August of that year. Prior to this he served as president of research and development at Calico. He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.
The Institute for Clinical and Economic Review (ICER) is a Boston-based independent nonprofit organization that seeks to place a value on medical care by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures.
Perry Nisen is an American physician and the former chief executive officer (CEO) of the Sanford Burnham Prebys Medical Discovery Institute (SBP). He was appointed as CEO in August 2014, and held the Donald Bren Chief Executive Chair.
Shenzhen International BT Leadership Summit is a biology-focused business conference. It is held each year in September. It is arranged by the Shenzhen Municipal People's Government. It is held at the Shenzhen Convention and Exhibition Center.
C. Glenn Begley is a hematologist and oncologist who was the CEO of BioCurate, an Australia-based joint venture between the University of Melbourne and Monash University that was launched in 2016. Previously, he worked at the California-based biotech company Akriveia Therapeutics as their chief scientific officer. His other previous positions include global head of hematology and oncology research at Amgen, senior vice president and chief scientific officer at TetraLogic Pharmaceuticals, and executive director of the Western Australian Institute of Medical Research.
William Pao is an oncologist and Executive Vice President and Chief Development Officer of Pfizer. He was previously the head of Pharma Research and Early Development (pRED) at Roche and a professor of medicine at the Vanderbilt University Medical Center. He is best known for his work in molecular oncology and cancer genomics.
Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.
Darrick Carter is an American biochemist/biophysicist, inventor, and entrepreneur. He is known for developing various therapeutics and vaccines, such as saRNA COVID-19 vaccine, influenza vaccine, and tuberculosis vaccine. Currently, he is the CEO of Compliment Corporation, and PAI Life Sciences Incorporated, as well as Founder of HDT Bio Corporation. He also holds two affiliate Professorships at the University of Washington in the Schools of Medicine and in Global Health.
References
- ↑ "John Reed lands in the top R&D post at J&J in his latest Big Pharma debut". Endpoints News.
- ↑ "Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D | Johnson & Johnson". Content Lab U.S.
- ↑ "The Burnham Institute's John C. Reed on the Birth of Cell-Death Research".
- ↑ Pollack, Andrew (15 January 2013). "Roche Hires Academic to Take Lead on Research". The New York Times.
| International | |
|---|---|
| National | |
| Other | |
   | This biographical article related to medicine in the United States is a stub. You can help Wikipedia by expanding it. |